UK Platform Trial Puts Repurposed Drugs to Work Against Alzheimer’s Disease
A new UK clinical trial is asking a blunt question with major bedside stakes: can medicines already used for type 2 diabetes and ADHD slow the cognitive and functional decline of Alzheimer’s disease? The study, known as AD-SMART, has begun enrollment with Angela Bucksey, 67, the first participant to start treatment. Investigators are testing metformin and atomoxetine in parallel, using a design built to move faster than the traditional one-drug, one-trial model that has long slowed dementia research.
Angela Bucksey’s decision to join the study reflects a familiar reality for families facing a diagnosis of Alzheimer’s disease: medication choices are limited, and the disease often advances while patients wait for answers. Her account of feeling determined not to let the diagnosis define her captures the emotional logic of trial participation, but the scientific logic is just as important. Alzheimer’s remains the most common form of dementia in the UK, affecting around 600,000 people, and any strategy that can shorten the path from hypothesis to usable evidence has immediate clinical relevance.
A Multi-Arm Design Built to Replace Slow, Linear Testing
AD-SMART is structured as a multi-arm, multi-stage platform trial, a model that allows several therapies to be evaluated within the same overall framework and compared with placebo. In practical terms, this design gives participants a higher chance of receiving an active drug than in a standard single-arm study. It also allows treatments that fail to show benefit to be removed quickly, while promising candidates can be added without having to start the entire process from zero.
The study design matters because Alzheimer’s drug development has often moved in slow, sequential steps, with long gaps between early signals and meaningful conclusions. Here, the goal is to compress that timeline. Scientists expect the first round of drug evaluation to finish in 2030, and additional treatments are likely to be layered into the platform before then. The structure borrows from research methods already used in cancer and motor neurone disease, where flexible trial architecture has helped accelerate decision-making.
The trial’s primary interest is not a biomarker or a narrow laboratory measure. Investigators want to know whether treatment changes the outcomes people and families actually experience: memory, thinking, and the ability to manage everyday life. In Alzheimer’s care, those domains are the difference between preserving independence and sliding into increasing dependence.
Why Metformin and Atomoxetine Were Chosen
The two first drugs selected for AD-SMART were identified by an international expert panel. Metformin, widely used in type 2 diabetes, and atomoxetine, prescribed for ADHD, were chosen because both may reduce brain inflammation, a process believed to contribute to neurodegeneration. That biological rationale is plausible enough to justify testing, even though neither drug was originally developed for dementia.
Inflammation in the brain is increasingly viewed as more than background noise in Alzheimer’s disease. It can interact with neuronal injury, synaptic dysfunction, and progressive loss of cognitive reserve. If a drug can dampen that inflammatory cascade, the effect may be less dramatic than a cure but still clinically meaningful: slower decline, delayed loss of function, and more time in which a person can remain engaged in daily life. For patients and carers, even modest shifts in trajectory can shape the entire course of care.
One sentence carries the weight of the trial’s biological premise: these drugs are being repurposed because the same pathways that influence metabolism and attention may also intersect with neuroinflammation in the aging brain.
What Success Will Look Like at the Bedside
For the study to succeed, the drugs will need to show more than a statistical signal. They must improve cognition and preserve the ability to carry out ordinary activities. Prof Paresh Malhotra, chief investigator and group leader at the UK Dementia Research Institute Centre for Care Research & Technology at Imperial College London, framed the problem directly: patients and carers care about whether people can think clearly and remain functionally independent.
That endpoint is clinically important because Alzheimer’s treatment has often been judged by surrogate markers that do not fully reflect the lived experience of the disease. A therapy that leaves cognition unchanged but does not help someone dress, cook, or navigate familiar routines offers little practical value. AD-SMART is set up to measure those real-world consequences through regular health checks and cognitive testing across the study period.
Around 1,200 participants with mild to moderate Alzheimer’s disease will be recruited at more than 30 sites across the UK. Early recruitment sites are already open in Cambridgeshire, Surrey, London, Southampton and Edinburgh. The broad geographic spread should help the trial access a diverse patient pool while keeping the logistical burden manageable for families already dealing with a complex diagnosis.
Family Experience and the Meaning of Trial Participation
Steve Bucksey, Angela’s husband and study partner, described the trial as a way back from despair after a diagnosis he called non-recoverable. That reaction is common in dementia care, where treatment conversations can quickly become conversations about decline rather than recovery. Trial participation changes the emotional frame. It creates a concrete action at a time when many families feel trapped by waiting.
There is also a social effect. People who know a family is enrolled in a drug trial may respond with encouragement rather than pity. In chronic neurodegenerative disease, that shift can matter as much as any single clinic visit. It can reduce the sense that a diagnosis has shut down agency, even when the underlying disease remains unchanged.
Dr Sheona Scales of Alzheimer’s Research UK stressed that time is precious for people living with the disease and that more treatment options are urgently needed. Her point fits the larger logic of the study. Alzheimer’s progression does not pause while the research enterprise works through conventional pipelines, and the longer it takes to test a candidate, the longer patients wait without options.
What the Trial Can and Cannot Answer Yet
AD-SMART is an ambitious attempt to rethink how dementia medicines are tested, but it is still an early-stage treatment program. The first evaluation window will stretch to 2030, so the immediate findings will be about signal detection rather than final proof of clinical benefit. Additional therapies may join the platform before that first readout, which makes the study more adaptable but also more complex to interpret over time.
No one can infer from the launch itself that either metformin or atomoxetine will work in Alzheimer’s disease. The trial is built precisely because that answer is not yet known. What it can do is create a faster route to the truth, with enough flexibility to drop weak candidates and retain the drugs that show a real effect on cognition and daily functioning. For a disease that has resisted repeated attempts at drug development, that faster route may matter as much as any single compound now entering the trial.